Evidence map›Paper›PMID 31829410›Full record

Observational studyJapanese journal of clinical oncology2020

Thymic epithelial tumor treatment in Japan: analysis of hospital cancer registry and insurance claims data, 2012-2014.

Hiroaki Kanemura, Tomohide Tamura, Naoki Nishimura, Daiki Kobayashi, Takahiro Higashi

Open access · hybridAbstract readObservational Study
In one paragraph

Observational study in Japanese journal of clinical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Diagnostic value of apparent diffusion coefficient in predicting pathological T stage in patients with thymic epithelial tumor.Cancer imaging : the official publication of the International Cancer Imaging Society · 2022
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Hiroaki KanemuraDepartment of Pulmonary Medicine, Thoracic Center, St. Luke's International Hospital, Tokyo, Japan.
Tomohide TamuraDepartment of Pulmonary Medicine, Thoracic Center, St. Luke's International Hospital, Tokyo, Japan.
Naoki NishimuraDepartment of Pulmonary Medicine, Thoracic Center, St. Luke's International Hospital, Tokyo, Japan.
Daiki KobayashiDepartment of Epidemiology, St. Luke's International University Graduate School of Public Health, Tokyo, Japan.
Takahiro HigashiDivision of Health Services Research, Center for Cancer Control and Information Services, National Cancer Center, Tokyo, Japan.
St. Luke's International Hospital · JPSt. Luke's International University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThymic epithelial tumors are a rare type of neoplasm. Accordingly, it is difficult to perform phase III trials in patients with thymic epithelial tumors, and thus, no standard treatment has been established for these tumors. In this study, we aimed to investigate the current status of thymic epithelial tumor treatment in Japan.

methodsThis retrospective observational study enrolled patients with thymic epithelial tumor whose data were recorded in a nationwide Hospital-based Cancer Registry that was linked with health insurance claims data for the registered patients between 2012 and 2014. The patients' treatment details were obtained from a health insurance claims database.

resultsA total of 813 patients with thymoma and 547 with thymic carcinoma were included in the analysis. Overall, 549 (67.5%) thymoma patients underwent surgical resection alone. Among patients with thymic carcinoma, 230 (42.0%) underwent initial surgery, and 124 (53.9%) received subsequent radiotherapy and chemotherapy. Chemotherapy regimens varied across the hospitals; overall, 21 and 22 regimens were used to treat thymoma and thymic carcinoma, respectively. Platinum-based combination regimens were predominantly selected for both diseases.

conclusionsThis study revealed the real-world patterns of thymic epithelial tumor treatment in Japan. Although the nature of this study did not enable the determination of optimal treatment strategies, the simultaneous analysis of nationwide registry, insurance, efficacy and prognostic data may contribute to the establishment of a standard treatment strategy for rarely occurring cancers such as thymic epithelial tumor.

Indexed as

AdolescentAdultAgedAged, 80 and overCancer Care FacilitiesCombined Modality TherapyDatabases, FactualData ManagementFemaleHospitalsHumansInsurance Claim ReviewJapanMaleMiddle AgedNeoplasms, Glandular and Epithelialchemotherapycombined modality therapythymic carcinomathymoma

Identifiers

PMID31829410
PMCPMC7061247
OpenAlexW2996343176

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.